Physician profile
Kashif Anwar
NPI 1114931045
$1,211.72
in general payments reported to CMS, 2019-2025
23 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $182 · 2021: $98.77 · 2022: $204 · 2023: $95.95 · 2024: $315 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $124.44 | 2019-2024 | |
| Glaxosmithkline, LLC. | $113.35 | 2019-2025 | Bexsero |
| Gm Pharmaceuticals, INC. | $98.60 | 2024 | Vanacof |
| Supernus Pharmaceuticals, INC. | $95.82 | 2024 | Qelbree |
| Cranial Technologies, INC | $91.21 | 2019-2025 | Doc Band |
| Seqirus USA INC | $83.09 | 2022-2025 | Flucelvax |
| Sanofi Pasteur INC. | $81.87 | 2019-2024 | |
| Adlon Therapeutics L.P. | $65.58 | 2020-2021 | |
| Tris Pharma INC | $57.80 | 2019-2020 | |
| Sobi, INC | $53.98 | 2021-2022 | |
| Genentech USA, INC. | $50.60 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.58 | 2021-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Phadia US INC. | $39.91 | 2022-2023 | Immunocap |
| Pfizer INC. | $39.73 | 2025 | |
| Shire North American Group INC | $33.06 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $23.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.15 | 2022 | |
| Grifols USA, LLC | $19.65 | 2025 | Prolastin-C Liquid |
| Cipher Pharmaceuticals US LLC | $16.63 | 2025 | Natroba, Spinosad |
| Novo Nordisk INC | $16.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.18 | 2025 | Zoryve |
| Aytu Biopharma, INC. | $13.72 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.